| Autor: |
Stegantseva, Maria V., Shinkevich, Veronika A., Tumar, Elena M., Meleshko, Alexander N. |
| Předmět: |
|
| Zdroj: |
Cancer Immunology, Immunotherapy; 2020, Vol. 69 Issue 12, p2613-2622, 10p |
| Abstrakt: |
Neuroblastoma is an example of a difficult-to-treat tumor with high incidence of relapse. DNA vaccination could be applied as a relapse prophylactic option for patients with high-risk neuroblastoma. Its efficacy depends directly on a target antigen of choice and a delivery method. Three neuroblastoma-associated antigens (tyrosine hydroxylase, Survivin, PHOX2B) and two delivery methods were investigated. Our data suggest that antigen PHOX2B is a more immunogenic target that induces cellular immune response and tumor regression more effectively than tyrosine hydroxylase and Survivin. Immunogenicity testing revealed that the delivery of DNA vaccine by Salmonella enterica was accompanied by a stronger immune response (cytotoxicity and IFNγ production) than that by DNA–polyethylenimine conjugate. Nevertheless, intramuscular immunization with PEI led to higher decrease of tumor volume compared to that after oral gavage with Salmonella vaccine. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink